Abstract 551: A Novel Retrievable Drug Delivery Stentgraft To Enhance Paclitaxel Delivery For Restenosis

• DOI: 10.1161/atvb.43.suppl_1.551
• Publication Date: 2023-10-02T14:09:33Z
• Authors: Jordan F Stafford; Dahlia Kenawy; Foued Amari; Saami K Yazdani; Bryan Tillman
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

Introduction: Half of vascular interventions will fail in under 5 years due to restenosis. While drug coated balloons (DCB) are used minimize restenosis, there several disadvantages: 1) Limitations the amount that can be adhered a balloon, 2) Significant is washed off balloon by circulation and 3) There limits on time inflation ischemia concerns. We developed dumbbell shaped, retrievable delivery stentgraft (RDDS) isolates segment artery with an outer chamber ( OC ) (Fig 1A). The center lumen stent maintains distal perfusion allow longer exposure this removed after use. Methods: A RDDS was fashioned from laser cut nitinol scaffold, covered polymer infusion cannula installed B). In porcine model, bilateral common iliac arteries were dilated plain angioplasty simulate endovascular intervention. Next commercial DCB paclitaxel (PXL) treat one iliac, while infused similar dose PXL contralateral iliac. Vessels serum had quantitation liquid chromatography-mass spectrophotometry. Results: Angiographically, maintained flow isolated arterial wall for C, D). Blood samples treated areas demonstrated lower concentrations during treatment compared (10.50 ± 0.77 vs. 2310.07 471.69 ng/mL, p < 0.0001). equivalent target vessel between two approaches (33.85 8.78 41.45 12.51 ng/mg, = 0.251, DCB). Conclusions: angiographically artery, maintaining perfusion. Moreover, DCB, able prevent loss effectively deliver wall. This study concludes chambered stentgrafts may have role locoregional delivery.